The effects of chronomodulated therapy with 5-fluorouracil (5-Fu) and folinic acid (Fa) on the toxicity and quality of life in patients with advanced gastric cancer

Biological Rhythm Research

Volumn 35, Issue 4-5, 2004, Pages 259-268

  Yalcin, Bulent ^a   Akbulut, Hakan ^a   Buyukcelik, Abdullah ^a   Sencan, Orhan ^b   Demirkazik, Ahmet ^a   Onur, Handan ^a   Senler, Filiz Cay ^a   Dincol, Dilek ^a   Icli, Fikri ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b SSK Etlik Ihtisas Hospital   (Turkey)

Author keywords

Chronotherapy; Fluorouracil; Gastric cancer; Quality of life

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

CANCER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CHRONOMODULATED THERAPY; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER METASTASIS; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PERITONEUM METASTASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER;

EID: 17144372219     PISSN: 09291016     EISSN: 17444179     Source Type: Journal    
DOI: 10.1080/09291010400011324A     Document Type: Article

References (31)

1. Abrahamsen JF, Smaaland R, Sandberg S, Aakvaag A, Lote K (1993): Circadian variation in serum cortisol and circulating neutrophils are markers for circadian variation of bone marrow proliferation in cancer patients. Eyr J Haematol 50(4): 206-212.
2. Akbulut H, Akbulut KG, Icli F, Buyukcelik A (2003): Daily variations of plasma malondialdehyde levels in patients with early breast cancer. Cancer Detect Prev 27(2): 122-126.
3. Akbulut H, Icli F, Buyukcelik A, Akbulut KG, Demirci S (1999): The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer. J Pineal Res 26(1): 1-8.
4. Bailleul F, Lévi F, Reimberg A, Mathe G (1986): Interindividual differences in the circadian hematological time structure of cancer patients. Chronobiol Int 3(1): 47-54.
5. Bertolini R, Focan C, Bartholome F, Baro V (1995): Comparative psychological aspects of two different types of chemotherapeutic administration (chronotherapy vs traditional chemotherapy) on quality of life of cancer patients of advanced stage. In Vivo 9(6): 583-587.
6. Buchi KN, Moore JG, Hrushesky WJ, Sothern RB, Rubin NH (1991): Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 101(2): 410-415.
7. Clayton F, Tessnow KA, Fang JC, Holden JA, Moore JG (2002): Circadian variation of topoisomerase II-alpha in human rectal crypt epithelium: implications for reduction of toxicity of chemotherapy. Mod Pathol 15(11): 1191-1196.
8. Dincol D, Akbulut A, Buyukcelik A, Icli F (2000): Diurnal variations of serum GM-CSF levels. Cytokine 12(7): 115-155.
9. Focan C, Levi F, Kreutz F, Focan-Henrard D, Lobelle JP, Adam R, Dallemagne B, Jehaes C, Markiewicz S, Weerts J, Bismuth H, Jasmin C, Misset JL (1999): Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. Anticancer Drugs 10(4): 385-392.
10. Furuya Y, Yamamoto K, Kohno N, Yamamoto M, Saitoh Y (1995): Serum concentrations of 5-fluorouracil achieved with nocturnal constant-rate infusion in patients with disseminated cancer. Cancer Lett 94(2): 207-211.
11. Haus E (1996): Biologic rhythms in hematology. Pathol Biol (Paris) 44(7): 618-630.
12. Haus E, Halberg F, Scheving LE, Simpson H (1979): International Cancer Research Workshop on 'Chronotherapy of cancer - a critical evaluation' sponsored by the International Cancer Research Data Bank of the United States of America, and administered by the International Union Against Cancer. Int J Chronobiol 6(2): 67-107.
13. Hrushesky WJ, von Roemeling R, Lanning RM, Rabatin JT (1990): Circadian-shaped infusion of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8(9): 1504-1513.
14. Kelsen D, Atiq OT (1991): Therapy of upper gastrointestinal tract cancers. Curr Probl Cancer 15(5): 235-294.
15. Levi F (1987): Chronobiology and cancer. Pathol Biol (Paris) 35(6): 960-968.
16. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L (1994): Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic asid (leucovorin) in patients with colorectal cancer metastasis: A randomized multi-institutional trial. J Natl Cancer Inst 86(21): 1608-1617.
17. Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ (2003): Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther 2: 105-111.
18. Marra G, Anti M, Percesepe A, Armelao F, Ficarelli R, Coco C, Rinelli A, Vecchio FM, D'Arcangelo E (1994): Circadian variations of epithelial cell proliferation in human rectal crypts. Gastroenterology 106(4): 982-987.
19. Mormont MC, Lévi F (1997): Circadian-system alterations during cancer processes: a review. Int J Cancer 70(2): 241-247.
20. Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset JL, Touitou Y, Levi F (2000): Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6(8): 3038-3045.
21. Nelson DH, Sandberg AA, Palmer JG, Tyler FH (1952): Blood levels of 17-hydroxycorticosteroids following the administration of adrenal steroids and their elation to levels of circulating leukocytes. J Clin Invest 31(9): 343-849.
22. Ponassi A, Morra L, Bonanni F, Molinari A, Gigli G, Vercelli M, Sacchetti C (1979): Normal range of blood colony-forming cells (CFU-C) in humans. Blut 39(4): 257-263.
23. Ralph MR, Menaker M (1988): A mutation of the circadian system in golden hamsters. Science 241(4870): 1225-1227.
24. Reinberg A, Schuller E, Delasnerie N, Clench J, Helary M (1977): Circadian and circannual rhythms in the blood (leucocytes, total proteins, IgA, IgG and IgM) of young healthy adults. Nouv Presse Med 6(41): 3819-3823.
25. Smaaland R, Laerum OD, Abrahamsen JF, Sothern RB, Lote K (1995): Cytokinetic circadian patterns in human host and tumor. J Infus Chemother 5(1): 11-14.
26. Smaaland R, Laerum OD, Lote K, Sletvold O, Sothern RB, Bjerknes R (1991): DNA syntesis in human bone marrow is circadian stage dependent. Blood 77(12): 2603-2611.
27. Sothern RB, Smaaland R, Moore JG (1995): Circannual rhythm in DNA synthesis (S-phase) in healthy human bone marrow and rectal mucosa. FASEB J 9(5): 397-403.
28. Touitou Y, Lévi F, Bogdan A, Benavides M, Bailleul F, Misset JL (1995): Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors. J Cancer Res Clin Oncol 121(3): 181-188.
29. von Roemeling R (1991): The therapeutic index of cytotoxic chemotherapy depends upon circadian drug time. Ann NY Acad Sci 618: 292-311.
30. von Roemeling R, Hrushesky WJ (1989): Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 7: 1710-1719.
31. World Health Organization (1979): WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, WHO. WHO Offset publication No. 48.